Fang Chunju, He Xuanlu, Tang Fei, Wang Zi, Pan Cong, Zhang Qi, Wu Jing, Wang Qinglan, Liu Daishun, Zhang Yu
Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.
School of Clinical Medicine, Zunyi Medical University, Zunyi, China.
Front Immunol. 2025 Apr 2;16:1561719. doi: 10.3389/fimmu.2025.1561719. eCollection 2025.
Lung cancer (LC) and tuberculosis (TB) represent two major global public health issues. Prior evidence has suggested a link between TB infection and an increased risk of LC. As advancements in LC treatment have led to extended survival rates for LC patients, the co-occurrence of TB and LC has grown more prevalent and poses novel clinical challenges. The intricate molecular mechanisms connecting TB and LC are closely intertwined and many issues remain to be addressed. This review focuses on resemblance between the immunosuppression in tumor and granuloma microenvironments, exploring immunometabolism, cell plasticity, inflammatory signaling pathways, microbiomics, and up-to-date information derived from spatial multi-omics between TB and LC. Furthermore, we outline immunization-related molecular mechanisms underlying these two diseases and propose future research directions. By discussing recent advances and potential targets, this review aims to establish a foundation for developing future therapeutic strategies targeting LC with concurrent TB infection.
肺癌(LC)和结核病(TB)是两个主要的全球公共卫生问题。先前的证据表明,结核感染与肺癌风险增加之间存在联系。随着肺癌治疗的进展提高了肺癌患者的生存率,结核病和肺癌的共存变得更加普遍,并带来了新的临床挑战。连接结核病和肺癌的复杂分子机制紧密相连,许多问题仍有待解决。本综述重点关注肿瘤和肉芽肿微环境中免疫抑制之间的相似性,探讨免疫代谢、细胞可塑性、炎症信号通路、微生物组学以及结核病和肺癌之间空间多组学的最新信息。此外,我们概述了这两种疾病潜在的免疫相关分子机制,并提出了未来的研究方向。通过讨论最新进展和潜在靶点,本综述旨在为制定针对合并结核病感染的肺癌的未来治疗策略奠定基础。